CervoMed (CRVO) Stock Price
CervoMed Price
Over the last 19 years CervoMed grew revenue by 13.2% annually, reaching 4.01 M USD. For CervoMed, the net margin of -673.1% is up versus -1,991.9% a few years ago. The consensus 12-month price target for CervoMed is 20.40 USD, about 633.7% above where the stock trades today. Of 14 analysts, 13 rate the stock a buy — an overall Buy consensus. The stock trades about 24% above its 52-week low.
CervoMed stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of CervoMed over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how CervoMed stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing CervoMed's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | CervoMed Price |
|---|---|
| 8/5/2026 | 2.78 USD |
| 8/4/2026 | 2.74 USD |
| 8/3/2026 | 2.60 USD |
| 7/31/2026 | 2.58 USD |
| 7/30/2026 | 2.52 USD |
| 7/29/2026 | 2.47 USD |
| 7/27/2026 | 2.69 USD |
| 7/23/2026 | 2.67 USD |
| 7/22/2026 | 2.78 USD |
| 7/21/2026 | 2.89 USD |
| 7/20/2026 | 2.79 USD |
| 7/17/2026 | 3.08 USD |
| 7/16/2026 | 3.14 USD |
| 7/15/2026 | 3.07 USD |
| 7/14/2026 | 3.08 USD |
| 7/13/2026 | 3.28 USD |
| 7/10/2026 | 3.57 USD |
| 7/9/2026 | 3.74 USD |
| 7/8/2026 | 3.40 USD |
| 7/7/2026 | 3.42 USD |
| 7/6/2026 | 3.57 USD |
| 7/2/2026 | 3.55 USD |
| 7/1/2026 | 3.69 USD |
| 6/30/2026 | 3.10 USD |
| 6/29/2026 | 3.15 USD |
| 6/26/2026 | 3.49 USD |
| 6/25/2026 | 3.35 USD |
| 6/24/2026 | 3.26 USD |
| 6/23/2026 | 3.72 USD |
| 6/22/2026 | 4.36 USD |
| 6/18/2026 | 4.24 USD |
| 6/17/2026 | 3.81 USD |
| 6/16/2026 | 4.52 USD |
| 6/15/2026 | 2.48 USD |
| 6/12/2026 | 2.45 USD |
| 6/11/2026 | 2.44 USD |
| 6/10/2026 | 2.25 USD |
| 6/9/2026 | 2.89 USD |
| 6/8/2026 | 2.91 USD |
| 6/5/2026 | 2.94 USD |
| 6/4/2026 | 3.12 USD |
| 6/3/2026 | 2.97 USD |
| 6/2/2026 | 3.00 USD |
| 6/1/2026 | 3.00 USD |
| 5/29/2026 | 3.11 USD |
| 5/28/2026 | 3.14 USD |
| 5/27/2026 | 3.04 USD |
| 5/26/2026 | 3.05 USD |
| 5/22/2026 | 3.06 USD |
| 5/21/2026 | 3.09 USD |
| 5/20/2026 | 3.24 USD |
| 5/19/2026 | 2.89 USD |
| 5/18/2026 | 3.04 USD |
| 5/15/2026 | 3.44 USD |
| 5/14/2026 | 3.73 USD |
| 5/13/2026 | 3.72 USD |
| 5/12/2026 | 3.77 USD |
| 5/11/2026 | 3.80 USD |
| 5/8/2026 | 3.95 USD |
| 5/7/2026 | 3.80 USD |
| 5/6/2026 | 3.83 USD |
| 5/5/2026 | 3.73 USD |
| 5/4/2026 | 3.70 USD |
| 5/1/2026 | 3.71 USD |
| 4/30/2026 | 3.69 USD |
| 4/29/2026 | 3.65 USD |
| 4/28/2026 | 3.71 USD |
| 4/27/2026 | 3.82 USD |
| 4/24/2026 | 3.88 USD |
| 4/23/2026 | 3.79 USD |
| 4/22/2026 | 3.94 USD |
| 4/21/2026 | 3.89 USD |
| 4/20/2026 | 3.97 USD |
| 4/17/2026 | 3.98 USD |
| 4/16/2026 | 3.99 USD |
| 4/15/2026 | 4.04 USD |
| 4/14/2026 | 4.04 USD |
| 4/13/2026 | 4.01 USD |
| 4/10/2026 | 3.83 USD |
| 4/9/2026 | 4.03 USD |
| 4/8/2026 | 4.04 USD |
| 4/7/2026 | 3.84 USD |
| 4/6/2026 | 3.98 USD |
| 4/2/2026 | 4.14 USD |
| 4/1/2026 | 4.00 USD |
| 3/31/2026 | 3.94 USD |
| 3/30/2026 | 3.62 USD |
| 3/27/2026 | 3.72 USD |
| 3/26/2026 | 3.92 USD |
| 3/25/2026 | 4.04 USD |
| 3/24/2026 | 3.92 USD |
| 3/23/2026 | 4.02 USD |
| 3/20/2026 | 4.02 USD |
| 3/19/2026 | 4.23 USD |
| 3/18/2026 | 4.24 USD |
| 3/17/2026 | 4.53 USD |
| 3/16/2026 | 4.31 USD |
| 3/13/2026 | 4.25 USD |
| 3/12/2026 | 4.33 USD |
| 3/11/2026 | 4.42 USD |
| 3/10/2026 | 4.86 USD |
| 3/9/2026 | 4.54 USD |
| 3/6/2026 | 4.11 USD |
| 3/5/2026 | 4.01 USD |
| 3/4/2026 | 4.02 USD |
| 3/3/2026 | 4.01 USD |
| 3/2/2026 | 3.89 USD |
| 2/27/2026 | 3.99 USD |
| 2/26/2026 | 4.40 USD |
| 2/25/2026 | 4.39 USD |
| 2/24/2026 | 4.79 USD |
| 2/23/2026 | 4.64 USD |
| 2/20/2026 | 4.63 USD |
| 2/19/2026 | 5.23 USD |
| 2/18/2026 | 4.93 USD |
| 2/17/2026 | 4.54 USD |
| 2/13/2026 | 4.72 USD |
| 2/12/2026 | 4.53 USD |
| 2/11/2026 | 4.80 USD |
| 2/10/2026 | 5.10 USD |
| 2/9/2026 | 5.50 USD |
| 2/6/2026 | 5.31 USD |
| 2/5/2026 | 4.60 USD |
| 2/4/2026 | 4.67 USD |
| 2/3/2026 | 4.83 USD |
| 2/2/2026 | 4.87 USD |
| 1/30/2026 | 5.15 USD |
| 1/29/2026 | 5.17 USD |
| 1/28/2026 | 5.40 USD |
| 1/27/2026 | 6.00 USD |
| 1/26/2026 | 5.77 USD |
| 1/23/2026 | 6.28 USD |
| 1/22/2026 | 6.58 USD |
| 1/21/2026 | 6.64 USD |
| 1/20/2026 | 6.99 USD |
| 1/16/2026 | 7.28 USD |
| 1/15/2026 | 7.08 USD |
| 1/14/2026 | 6.99 USD |
| 1/13/2026 | 7.54 USD |
| 1/12/2026 | 7.59 USD |
| 1/9/2026 | 7.74 USD |
| 1/8/2026 | 7.87 USD |
| 1/7/2026 | 7.95 USD |
| 1/6/2026 | 7.55 USD |
| 1/5/2026 | 7.81 USD |
| 1/2/2026 | 7.79 USD |
| 12/31/2025 | 7.90 USD |
| 12/30/2025 | 7.98 USD |
| 12/29/2025 | 7.82 USD |
| 12/26/2025 | 8.08 USD |
| 12/24/2025 | 8.48 USD |
| 12/23/2025 | 8.42 USD |
| 12/22/2025 | 8.12 USD |
| 12/19/2025 | 7.60 USD |
| 12/18/2025 | 7.90 USD |
| 12/17/2025 | 7.99 USD |
| 12/16/2025 | 8.35 USD |
| 12/15/2025 | 8.35 USD |
| 12/12/2025 | 8.45 USD |
| 12/11/2025 | 8.19 USD |
| 12/10/2025 | 8.67 USD |
| 12/9/2025 | 8.63 USD |
| 12/8/2025 | 8.79 USD |
| 12/5/2025 | 8.69 USD |
| 12/4/2025 | 9.06 USD |
| 12/3/2025 | 8.28 USD |
| 12/2/2025 | 8.22 USD |
| 12/1/2025 | 9.22 USD |
| 11/28/2025 | 9.94 USD |
| 11/26/2025 | 9.94 USD |
| 11/25/2025 | 9.63 USD |
| 11/24/2025 | 9.27 USD |
| 11/21/2025 | 8.88 USD |
| 11/20/2025 | 9.01 USD |
| 11/19/2025 | 8.62 USD |
| 11/18/2025 | 8.30 USD |
| 11/17/2025 | 8.21 USD |
| 11/14/2025 | 7.68 USD |
| 11/13/2025 | 7.25 USD |
| 11/12/2025 | 7.41 USD |
| 11/11/2025 | 6.97 USD |
| 11/10/2025 | 6.90 USD |
| 11/7/2025 | 6.92 USD |
| 11/6/2025 | 7.29 USD |
| 11/5/2025 | 7.34 USD |
| 11/4/2025 | 7.02 USD |
| 11/3/2025 | 7.02 USD |
| 10/31/2025 | 7.05 USD |
| 10/30/2025 | 7.11 USD |
| 10/29/2025 | 6.88 USD |
| 10/28/2025 | 6.74 USD |
| 10/27/2025 | 7.02 USD |
| 10/24/2025 | 7.07 USD |
| 10/23/2025 | 7.08 USD |
| 10/22/2025 | 7.14 USD |
| 10/21/2025 | 7.22 USD |
| 10/20/2025 | 7.51 USD |
| 10/17/2025 | 7.08 USD |
| 10/16/2025 | 7.60 USD |
| 10/15/2025 | 8.10 USD |
| 10/14/2025 | 8.22 USD |
| 10/13/2025 | 8.01 USD |
| 10/10/2025 | 8.15 USD |
| 10/9/2025 | 8.54 USD |
| 10/8/2025 | 8.90 USD |
| 10/7/2025 | 8.53 USD |
| 10/6/2025 | 8.62 USD |
| 10/3/2025 | 8.70 USD |
| 10/2/2025 | 8.17 USD |
| 10/1/2025 | 8.03 USD |
| 9/30/2025 | 8.09 USD |
| 9/29/2025 | 8.08 USD |
| 9/26/2025 | 8.28 USD |
| 9/25/2025 | 7.82 USD |
| 9/24/2025 | 8.11 USD |
| 9/23/2025 | 8.24 USD |
| 9/22/2025 | 8.16 USD |
| 9/19/2025 | 7.79 USD |
| 9/18/2025 | 8.10 USD |
| 9/17/2025 | 7.79 USD |
| 9/16/2025 | 8.11 USD |
| 9/15/2025 | 8.54 USD |
| 9/12/2025 | 8.85 USD |
| 9/11/2025 | 9.20 USD |
| 9/10/2025 | 9.52 USD |
| 9/9/2025 | 10.00 USD |
| 9/8/2025 | 9.99 USD |
| 9/5/2025 | 10.51 USD |
| 9/4/2025 | 10.21 USD |
| 9/3/2025 | 10.69 USD |
| 9/2/2025 | 10.10 USD |
| 8/29/2025 | 9.62 USD |
| 8/28/2025 | 9.32 USD |
| 8/27/2025 | 9.39 USD |
| 8/26/2025 | 9.56 USD |
| 8/25/2025 | 9.43 USD |
| 8/22/2025 | 9.13 USD |
| 8/21/2025 | 9.22 USD |
| 8/20/2025 | 9.23 USD |
| 8/19/2025 | 9.15 USD |
| 8/18/2025 | 9.83 USD |
| 8/15/2025 | 10.12 USD |
| 8/14/2025 | 10.19 USD |
| 8/13/2025 | 9.64 USD |
| 8/12/2025 | 9.40 USD |
| 8/11/2025 | 9.50 USD |
CervoMed Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
CervoMed Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e | 2031e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | 0.01 | 0.01 | – | – | – | – | 0.06 | 0.13 | 1.03 |
| – | – | – | – | – | – | – | – | 28.57 | -55.56 | – | – | – | – | 127.12 | 670.15 |
| – | – | – | – | – | – | – | -14.29 | -11.11 | -25.00 | – | – | – | -1.69 | -0.75 | -0.10 |
| -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 | -1.00 |
| -18.00 | -11.00 | -12.00 | -11.00 | -15.00 | -16.00 | -15.00 | -7.00 | -18.00 | -28.00 | -46.00 | -56.00 | -63.00 | -2.00 | -15.00 | – |
| – | – | – | – | – | – | – | -100.00 | -200.00 | -700.00 | – | – | – | -3.39 | -11.19 | – |
| -18.00 | -2.00 | -26.00 | -11.00 | -16.00 | -24.00 | -15.00 | -2.00 | -16.00 | -26.00 | -17.00 | -13.00 | -11.00 | -6.00 | -11.00 | 49.00 |
| 200.00 | -88.89 | 1,200.00 | -57.69 | 45.45 | 50.00 | -37.50 | -86.67 | 700.00 | 62.50 | -34.62 | -23.53 | -15.38 | -45.45 | 83.33 | -545.45 |
| 0.01 | 0.01 | 0.04 | 0.09 | 0.72 | 1.30 | 1.36 | 2.66 | 8.07 | 9.04 | 9.04 | 9.04 | 9.04 | 9.04 | 9.04 | 9.04 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales CervoMed generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue CervoMed retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare CervoMed's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares CervoMed has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against CervoMed's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
CervoMed stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
CervoMed Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
CervoMed business model & stock analysis
CervoMed Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
CervoMed historical P/E ratio, EBIT multiple, and P/S ratio
CervoMed annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
CervoMed shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
CervoMed stock splits
Current CervoMed forecasts and price targets in August 2026
Analyst Price Targets 2026CervoMed Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/17/2026 | -0.81USD | - | 0.00USD | - | 2026 Q2 |
| 5/19/2026 | -0.80USD | - | 61,200.00USD | - | 2026 Q1 |
| 3/16/2026 | -0.73USD | - | 859,717.00USD | - | 2025 Q4 |
| 11/11/2024 | -0.42USD | - | 3.13 MUSD | - | 2024 Q3 |
| 3/22/2024 | -0.97USD | - | 0.00USD | - | 2023 Q4 |
CervoMed shareholder structure
| % | Name |
|---|---|
8.78845% | |
8.33118% | |
8.33118% | |
5.20506% | |
3.92566% | |
0.72859% |
CervoMed Executives and Management Board
14 members · avg. age 60 · 21 % women
Mr. John Alam (63)
President, Chief Executive Officer, Director · since 2023
1.04 M USD
Management
Mr. William Elder (42)
Chief Financial Officer, General Counsel, Corporate Secretary
Ms. Kelly Blackburn (61)
Executive Vice President - Clinical Development
Dr. Mark De Rosch (61)
Executive Vice President - Regulatory and Government Affairs and Program Management
Dr. Marco Verwijs
Executive Vice President - Technical Operations
Mr. Pj Kelleher
Investor Relations · since 2024
Board of Directors
Dr. Robert Cobuzzi (60)
Director · since 2020
Dr. Joshua Boger (74)
Independent Chairman of the Board
Mr. Frank Zavrl (59)
Independent Director
Ms. Jane Hollingsworth (67)
Independent Director
Mr. Jeffrey Poulton (57)
Independent Director
Dr. Marwan Sabbagh (59)
Independent Director
Frequently asked questions about CervoMed
Analysts currently set an average price target of 22.88 USD for the CervoMed stock (median: 20.40 USD), implying +697.1 % versus the latest price. The consensus is based on 14 analyst ratings.
14 analysts currently rate the CervoMed stock: 13 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the CervoMed share trades at 2.41 EUR (2.78 USD).
The CervoMed share (CRVO) is listed on 2 stock exchanges, including: NASDAQ (DFFN), Frankfurt (DP8.F).
No history available for CervoMed.
The revenue cannot currently be calculated for CervoMed.
The expected profit of CervoMed is -17.46 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of CervoMed is currently -1.44. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the CervoMed stock.
The P/S cannot be calculated for CervoMed currently.
The Eulerpool Quality Score for CervoMed is 4/10.
The ISIN of CervoMed is US15713L1098. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of CervoMed is A3ES01. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of CervoMed is CRVO. The ticker symbol is used to trade CervoMed shares on the stock exchange.
CervoMed paid dividends every year for the past 0 years.
CervoMed is assigned to the 'Health' sector.
The dividends of CervoMed are distributed in USD.
CervoMed stock
CervoMed Peer Group
CervoMed Ticker
CervoMed FIGI
All fundamentals and in-depth analysis of CervoMed
Our stock analysis for CervoMed stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CervoMed. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.